{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:41:08Z","timestamp":1780638068987,"version":"3.54.1"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0223649","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T18:59:20Z","timestamp":1570733960000},"page":"e0223649","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals"],"prefix":"10.1371","volume":"14","author":[{"given":"Amandine","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Moore Boffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e8le","family":"Gayet-Ageron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-5510","authenticated-orcid":true,"given":"Nathalie","family":"Vernaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"pone.0223649.ref001","unstructured":"WHO. Global Hepatitis Report. [cited 2019 April 22]. Availabe from http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"pone.0223649.ref002","unstructured":"WHO. Combating Hepatits B and C by 2030. [cited 2017 December 12]. Availabe from: https:\/\/www.who.int\/hepatitis\/publications\/hep-elimination-by-2030-brief\/en\/."},{"key":"pone.0223649.ref003","unstructured":"WHO. Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. [cited 2019 April 22]. Availabe from: http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/. 2016."},{"issue":"6","key":"pone.0223649.ref004","doi-asserted-by":"crossref","first-page":"e0157098","DOI":"10.1371\/journal.pone.0157098","article-title":"Drug Pricing Evolution in Hepatitis C","volume":"11","author":"N Vernaz","year":"2016","journal-title":"PLoS One"},{"key":"pone.0223649.ref005","first-page":"w14649","article-title":"A buyers' club to improve access to hepatitis C treatment for vulnerable populations","volume":"148","author":"N Vernaz","year":"2018","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"pone.0223649.ref006","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s12879-018-3445-6","article-title":"Blood-borne and sexually transmitted infections: a cross-sectional study in a Swiss prison","volume":"18","author":"K Chacowry Pala","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"Suppl 5","key":"pone.0223649.ref007","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/j.dld.2014.09.023","article-title":"Epidemiology of hepatitis C in Europe","volume":"46","author":"F Negro","year":"2014","journal-title":"Dig Liver Dis"},{"key":"pone.0223649.ref008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijid.2018.03.004","article-title":"Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment","volume":"70","author":"Y Assefa","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0223649.ref009","doi-asserted-by":"crossref","first-page":"1586317","DOI":"10.1080\/16549716.2019.1586317","article-title":"Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?","volume":"12","author":"EJ Beck","year":"2019","journal-title":"Glob Health Action"},{"key":"pone.0223649.ref010","unstructured":"WTO. Intellectual Property (TRIPS)\u2014Part II\u2014Standards concerning the availability, scope and use of Intellectual Property Rights. [cited 2019 May 2]. Availabe from: https:\/\/www.wto.org\/english\/docs_e\/legal_e\/27-trips_04c_e.htm."},{"issue":"7","key":"pone.0223649.ref011","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2471\/BLT.12.115865","article-title":"Using TRIPS flexibilities to facilitate access to medicines","volume":"91","author":"D Nicol","year":"2013","journal-title":"Bull World Health Organ"},{"key":"pone.0223649.ref012","unstructured":"Vel\u00e1squez G. The Use of TRIPS Flexibilities for the Access to Hepatitis C Treatment. [cited 2018 October 24]. Availabe from: https:\/\/www.southcentre.int\/wp-content\/uploads\/2018\/10\/PB54_The-Use-of-TRIPS-Flexibilities-for-the-Access-to-Hepatitis-C-Treatment_EN.pdf. South Center. October 2018;54."},{"issue":"3","key":"pone.0223649.ref013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2471\/BLT.17.199364","article-title":"Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001\u20132016","volume":"96","author":"EF t Hoen","year":"2018","journal-title":"Bull World Health Organ"},{"key":"pone.0223649.ref014","unstructured":"Hoen EFMt. Practical Applications of the Flexibilities of the Agreement on Trade- Related Aspects of Intellectual Property Rights. Lessons beyond HIV for access to new essential medicines. [cited 2019 June 11] Availabe from: https:\/\/medicineslawandpolicyorg\/wp- content\/uploads\/2018\/03\/EllentHoen_dissertatie_Practical_Implications_2018pdf."},{"key":"pone.0223649.ref015","unstructured":"OFSP. M\u00e9dicaments Contre l\u2019h\u00e9patite C: Forte r\u00e9duction du prix et remboursement \u00e9tendu. [cited 2019 April 22]. Availabe from: https:\/\/www.bag.admin.ch\/bag\/fr\/home\/das-bag\/aktuell\/news\/news-26-06-2017.html."},{"key":"pone.0223649.ref016","unstructured":"Article 20 para. 2 a) of the Federal Act on Medicinal Products and Medical Devices (TPA) [cited 2019 September 10]. Available from: https:\/\/www.admin.ch\/opc\/en\/classified-compilation\/20002716\/index.html."},{"key":"pone.0223649.ref017","unstructured":"Article 48 of the Ordinance on licensing of medicinal products (AMBV). [cited 2019 September 10]. Available from: https:\/\/www.admin.ch\/opc\/en\/classified-compilation\/20180857\/index.html."},{"key":"pone.0223649.ref018","unstructured":"Swissmedic. Guideline on medicines and the Internet. [cited 2019 February 17]. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/market-surveillance\/medicinal-products-from-the-internet\/leitfaden-arzneimittel-aus-dem-internet.html"},{"issue":"7","key":"pone.0223649.ref019","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/liv.13157","article-title":"The use of generic medications for hepatitis C","volume":"36","author":"JA Freeman","year":"2016","journal-title":"Liver Int"},{"issue":"2","key":"pone.0223649.ref020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2055-6640(20)30257-0","article-title":"Bioequivalent pharmacokinetics for generic and originator hepatitis C direct- acting antivirals","volume":"4","author":"A Hill","year":"2018","journal-title":"J Virus Erad"},{"issue":"1","key":"pone.0223649.ref021","first-page":"84","article-title":"The brand of generic prescriptions","volume":"3","author":"BN Gangadhar","year":"2018","journal-title":"Indian J Med Ethics"},{"issue":"1","key":"pone.0223649.ref022","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1186\/s12913-017-2682-5","article-title":"\"No generics, Doctor!\" The perspective of general practitioners in two French regions","volume":"17","author":"B Riner","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"pone.0223649.ref023","first-page":"288","article-title":"Consumer choice between common generic and brand medicines in a country with a small generic market","volume":"21","author":"J Fraeyman","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"pone.0223649.ref024","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/pds.4205","article-title":"Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process","volume":"26","author":"AS Kesselheim","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0223649.ref025","unstructured":"Rhumorbarbe D. Acheter des m\u00e9dicaments sur internet: moins cher et plus risqu\u00e9? [cited 2019 June 25]. Availabe from: https:\/\/www.grea.ch\/sites\/default\/files\/article_7.pdf. D\u00c9PENDANCES.51:21\u20133."},{"key":"pone.0223649.ref026","unstructured":"F\u00e9d\u00e9ration romande des consommateurs. Achat en ligne de m\u00e9dicaments: m\u00e9fiez-vous des faux!. [cited 2019 June 25]. Avalailable from: https:\/\/www.frc.ch\/achat-en-ligne-de-medicaments\/."},{"key":"pone.0223649.ref027","unstructured":"IRACM. Falsification sur internet. [cited 2019 June 25]. Availabe from: http:\/\/www.iracm.com\/observatoire-thematique\/falsification-sur-internet\/."},{"key":"pone.0223649.ref028","unstructured":"COMPARIS. Commander ses m\u00e9dicaments sur internet-attention. [cited 2019 June 25]. Availabe from: https:\/\/fr.comparis.ch\/krankenkassen\/gesundheit-praevention\/information\/medikamente-ausland-bestellen."},{"key":"pone.0223649.ref029","unstructured":"Article 2 para 2 of the Federal Act on Research involving Human Beings (HRA) [cited 2019 September 10] Available from: https:\/\/wwwadminch\/opc\/en\/classified-compilation\/20061313\/indexhtml."},{"key":"pone.0223649.ref030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40545-016-0088-0","article-title":"Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy","volume":"9","author":"R Ravinetto","year":"2016","journal-title":"J Pharm Policy Pract"},{"key":"pone.0223649.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-6511-14-1","article-title":"A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study","volume":"14","author":"S Dunne","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"pone.0223649.ref032","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejps.2017.09.047","article-title":"The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference","volume":"111","author":"ML Chen","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"pone.0223649.ref033","first-page":"263","article-title":"Bioequivalence study of two fixed dose combination tablet formulations of lopinavir and ritonavir in healthy volunteers","volume":"59","author":"S Chachad","year":"2009","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"pone.0223649.ref034","doi-asserted-by":"crossref","first-page":"e0117214","DOI":"10.1371\/journal.pone.0117214","article-title":"Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France","volume":"10","author":"C Jacomet","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"pone.0223649.ref035","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/ph3082470","article-title":"Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?","volume":"3","author":"B Godman","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"pone.0223649.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5639\/gabij.2012.0101.007","article-title":"European payer initiatives to reduce prescribing costs through use of generics","volume":"1","author":"B Godman","year":"2012","journal-title":"GaBI Journal"},{"issue":"1","key":"pone.0223649.ref037","doi-asserted-by":"crossref","first-page":"13699","DOI":"10.1038\/s41598-018-32060-7","article-title":"Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study","volume":"8","author":"CH Liu","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0223649.ref038","unstructured":"WHO. Prequalification of Medicines by WHO. [cited 2019 May 9]. Available from:https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/prequalification-of-medicines-by-who."},{"key":"pone.0223649.ref039","unstructured":"Abbreviated New Drug Application (ANDA). [cited 2019 June 25]. Available from:https:\/\/www.fda.gov\/drugs\/types-applications\/abbreviated-new-drug-application-anda."},{"issue":"4","key":"pone.0223649.ref040","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25019","article-title":"The US Food and Drug Administration's tentative approval process and the global fight against HIV","volume":"20","author":"HS Chahal","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"pone.0223649.ref041","doi-asserted-by":"crossref","first-page":"e000651","DOI":"10.1136\/bmjgh-2017-000651","article-title":"Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment","volume":"3","author":"HS Chahal","year":"2018","journal-title":"BMJ Glob Health"},{"key":"pone.0223649.ref042","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1758-2652-13-35","article-title":"A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries","volume":"13","author":"B Waning","year":"2010","journal-title":"J Int AIDS Soc"},{"key":"pone.0223649.ref043","doi-asserted-by":"crossref","first-page":"d1694","DOI":"10.1136\/bmj.d1694","article-title":"The production of generic drugs in India","volume":"342","author":"J Love","year":"2011","journal-title":"BMJ"},{"key":"pone.0223649.ref044","unstructured":"Mylan Pharma GmbH. Launch of first generics. [cited 2019 June 9]. Availabe from: https:\/\/www.mylan.ch\/en-gb\/news\/2018\/launch-of-the-first-generics."},{"issue":"3","key":"pone.0223649.ref045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jceh.2017.08.003","article-title":"Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?","volume":"7","author":"M Premkumar","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"pone.0223649.ref046","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijid.2018.07.025","article-title":"High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C","volume":"75","author":"M Abozeid","year":"2018","journal-title":"Int J Infect Dis"},{"key":"pone.0223649.ref047","doi-asserted-by":"crossref","first-page":"9124604","DOI":"10.1155\/2018\/9124604","article-title":"Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C","volume":"2018","author":"L Tang","year":"2018","journal-title":"Interdiscip Perspect Infect Dis"},{"issue":"5","key":"pone.0223649.ref048","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40261-018-0622-8","article-title":"Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400\/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers","volume":"38","author":"ER Bendas","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"12","key":"pone.0223649.ref049","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/apt.14647","article-title":"Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection","volume":"47","author":"CH Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"pone.0223649.ref050","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/heapol\/czw062","article-title":"Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies","volume":"31","author":"WL Hamilton","year":"2016","journal-title":"Health Policy Plan"},{"key":"pone.0223649.ref051","unstructured":"Swissmedic. Action \u00ab PANGEA XI \u00bb: la Suisse participe \u00e0 la semaine d\u2019actiointernationale contre le commerce ill\u00e9gal de produits th\u00e9rapeutiques. [cited 2019 May 19]. Availabe from: https:\/\/www.swissmedic.ch\/swissmedic\/fr\/home\/medicaments-a-usage-humain\/surveillance-du-marche\/medicaments-par-internet\/mise-en-garde-au-sujet-des-medicaments-achetes-sur-internet\/aktion_pangeaxi.html."},{"issue":"9","key":"pone.0223649.ref052","doi-asserted-by":"crossref","first-page":"e0184165","DOI":"10.1371\/journal.pone.0184165","article-title":"Difam EPNMSG. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab","volume":"12","author":"A Petersen","year":"2017","journal-title":"PLoS One"},{"key":"pone.0223649.ref053","article-title":"Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet","author":"X Wang","year":"2019","journal-title":"Int J STD AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0223649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T13:29:10Z","timestamp":1611494950000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0223649"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0223649","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]}}}